INTRODUCTION: Results of Sofosbuvir based regimens for hepatitis C (HCV) recurrence after liver transplantation are available from well-designed clinical trials. Most of the data is from deceased donor liver transplant (DDLT) setting, and data on "real world" experience for HCV recurrence after living donor liver transplantation (LDLT) is limited. MATERIAL AND METHODS: Consecutive 78 patients who completed Sofosbuvir based HCV treatment after liver transplantation were included. Following Sofosbuvir based regimens were used; Sofosbuvir + Ribavirin (n = 58), Sofosbuvir + Ledipasvir ± Ribavirin (n = 5), Sofosbuvir + Daclatasvir ± Ribavirin (n = 15). Treatment was given for 12 weeks (triple therapy) or 24 weeks (dual therapy). RESULTS: A total of 74/78 (94.8%) patients achieved end of treatment response (ETR) while 4 did not achieve ETR. A total of 68/76 (89.4%) patients achieved sustained virological response at 12 weeks (SVR12). while 2 are waiting for 12 weeks follow up after ETR. Twelve patients had history of failed previous treatment with Peginterferon and Ribavirin after LDLT, all these patients achieved ETR and 11/12 had SVR12. There was no statistical difference in response rates between genotype 1 or 3. Eighteen patients (16 on Ribavirin) had hemoglobin < 8 g/dl; two patients complained fatigue in absence of anemia. CONCLUSION: Sofosbuvir based regimens are safe and highly effective in treatment of HCV recurrence after LDLT.
INTRODUCTION: Results of Sofosbuvir based regimens for hepatitis C (HCV) recurrence after liver transplantation are available from well-designed clinical trials. Most of the data is from deceased donor liver transplant (DDLT) setting, and data on "real world" experience for HCV recurrence after living donor liver transplantation (LDLT) is limited. MATERIAL AND METHODS: Consecutive 78 patients who completed Sofosbuvir based HCV treatment after liver transplantation were included. Following Sofosbuvir based regimens were used; Sofosbuvir + Ribavirin (n = 58), Sofosbuvir + Ledipasvir ± Ribavirin (n = 5), Sofosbuvir + Daclatasvir ± Ribavirin (n = 15). Treatment was given for 12 weeks (triple therapy) or 24 weeks (dual therapy). RESULTS: A total of 74/78 (94.8%) patients achieved end of treatment response (ETR) while 4 did not achieve ETR. A total of 68/76 (89.4%) patients achieved sustained virological response at 12 weeks (SVR12). while 2 are waiting for 12 weeks follow up after ETR. Twelve patients had history of failed previous treatment with Peginterferon and Ribavirin after LDLT, all these patients achieved ETR and 11/12 had SVR12. There was no statistical difference in response rates between genotype 1 or 3. Eighteen patients (16 on Ribavirin) had hemoglobin < 8 g/dl; two patients complained fatigue in absence of anemia. CONCLUSION: Sofosbuvir based regimens are safe and highly effective in treatment of HCV recurrence after LDLT.
Entities:
Keywords:
DAA, direct acting antivirals; DDLT, deceased donor liver transplant; ETR, end of treatment response; HCV, hepatitis C; LDLT, living donor liver transplantation; RVR, rapid virological response; SVR12; SVR12, sustained virological response at 12 weeks; Sofosbuvir; hepatitis C; living donor liver transplantation; recurrence
Authors: Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns Journal: Lancet Infect Dis Date: 2016-02-18 Impact factor: 25.071
Authors: Robert S Brown; Jacqueline G O'Leary; K Rajender Reddy; Alexander Kuo; Giuseppe J Morelli; James R Burton; R Todd Stravitz; Christine Durand; Adrian M Di Bisceglie; Paul Kwo; Catherine T Frenette; Thomas G Stewart; David R Nelson; Michael W Fried; Norah A Terrault Journal: Liver Transpl Date: 2016-01 Impact factor: 5.799
Authors: Leon Louis Seifert; Elena Vorona; Caroline Bester; Martin Stahl; Anna Hüsing; Susanne Beckebaum; Iyad Kabar; Hauke Heinzow; Hartmut H-J Schmidt Journal: Ann Transplant Date: 2015-09-22 Impact factor: 1.530
Authors: M Berenguer; L Ferrell; J Watson; M Prieto; M Kim; M Rayón; J Córdoba; A Herola; N Ascher; J Mir; J Berenguer; T L Wright Journal: J Hepatol Date: 2000-04 Impact factor: 25.083
Authors: Xavier Forns; Michael Charlton; Jill Denning; John G McHutchison; William T Symonds; Diana Brainard; Theo Brandt-Sarif; Paul Chang; Valerie Kivett; Lluís Castells; Martín Prieto; Robert J Fontana; Thomas F Baumert; Audrey Coilly; Maria Carlota Londoño; François Habersetzer Journal: Hepatology Date: 2015-03-20 Impact factor: 17.425
Authors: E J Gane; B C Portmann; N V Naoumov; H M Smith; J A Underhill; P T Donaldson; G Maertens; R Williams Journal: N Engl J Med Date: 1996-03-28 Impact factor: 91.245
Authors: Michael Charlton; Edward Gane; Michael P Manns; Robert S Brown; Michael P Curry; Paul Y Kwo; Robert J Fontana; Richard Gilroy; Lewis Teperman; Andrew J Muir; John G McHutchison; William T Symonds; Diana Brainard; Brian Kirby; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Didier Samuel; Xavier Forns; Norah A Terrault Journal: Gastroenterology Date: 2014-10-07 Impact factor: 22.682